Devyser Diagnostics AB (publ) (OM: DVYSR)
Health Care · Biotechnology · SE
Skr59.60
-5.99% today · -56.6% 1Y
Devyser Diagnostics AB (publ) (OM: DVYSR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $112.60M and employs 110 people.
Over the last twelve months the share price has lost 56.6%, trading between 57.80 and 159.60.
Tweenvest scores Devyser Diagnostics AB (publ) across four factors: quality 58/100, value 56/100, growth 100/100. Its strongest factor is growth.
DVYSR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $112.60M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- —
- Dividend yield
- —
- Beta (5Y)
- 0.79
- 52-week high
- Skr159.60
- 52-week low
- Skr57.80
- Avg volume (3M)
- —
- Shares outstanding
- 16.89M
- Employees
- 110
- Next earnings
- —
About Devyser Diagnostics AB (publ)
Headquartered in Hägersten, Sweden, and established in 2004, Devyser Diagnostics AB (publ) specializes in the development, manufacturing, and global sale of advanced diagnostic kits and solutions for DNA testing. The company's innovative products are crucial for genetic analysis in key medical areas, including hereditary diseases, oncology, and post-transplantation monitoring. Devyser offers a broad array of diagnostic tools, covering applications such as post-transplant management, thalassemia screening, and the detection of various cancers like breast, colorectal, and ovarian. Their portfolio also extends to non-invasive fetal RHD screening, diagnostics for inherited conditions, cystic fibrosis, cardiovascular issues, male infertility, and rapid aneuploidy analysis, complemented by essential accessories. These solutions are utilized for diverse purposes, from diagnosing genetic disorders and guiding targeted cancer treatments to ensuring thorough follow-up care for transplant patients. Furthermore, Devyser provides specialized software programs, including Amplicon Suite and Advyser, which facilitate the processing, analysis, and interpretation of test results, enabling efficient marker screening and patient sample tracking. The company's operations span Sweden, the broader European market, the Middle East, Africa, North and South America, and Asia.
- ISIN
- SE0016588867
- Founded
- 2004
- Listed since
- Dec 10, 2021
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $265.55 | +0.22% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.98 | +0.38% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.44 | +0.22% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.78 | +0.13% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $825.89 | -0.98% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $137.91 | -4.94% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.